丝氨酸/苏氨酸蛋白激酶1、异分支酸酶包含域1在胃癌组织中的表达及其诊断价值

doi:10.3969/j.issn.1006-5725.2025.13.013

Abstract

Abstract:

Objective To explore the expression of serine/threonine protein kinase 1 （AKT1） and Isochorismatase Domain-Containing 1 （ISOC1） in gastric cancer tissues and evaluate their diagnostic utility. Methods A total of 90 patients with gastric cancer who were diagnosed and treated in our hospital between March 2023 and September 2024 were recruited as the study subjects. The positive expression rates and positive scores of AKT1 and ISOC1 in cancer tissues and adjacent tissues were compared. The AKT1 and ISOC1 positive scores of gastric cancer patients with diverse characteristics were also compared. The Spearman correlation analysis was employed to examine the relationship between the expression of AKT1 and ISOC1 in cancer tissues and the clinical features of gastric cancer patients. A diagnostic model for gastric cancer， integrating AKT1 and ISOC1， was established using the Logistic regression model. Receiver operating characteristic （ROC） curves were plotted to analyze the area under the curve （AUC） value， sensitivity， and specificity of AKT1， ISOC1， and their combined diagnosis for gastric cancer. Results The positive expression rates and positive scores of AKT1 and ISOC1 in cancer tissues were significantly higher than those in paracancerous tissues （P < 0.05）. In gastric cancer patients， the expressions of AKT1 and ISOC1 were notably higher in patients with low differentiation， clinical stage Ⅰ~Ⅱ， invasion depth T₁_-₂， absence of lymph node metastasis， and no distant metastasis compared to those with moderate differentiation， clinical stage Ⅲ~Ⅳ， invasion depth T₃_-₄， and presence of lymph node metastasis and distant metastasis （P < 0.05）. Spearman's correlation analysis indicated that AKT1 and ISOC1 were positively correlated with the degree of differentiation， clinical stage， lymph node metastasis， invasion degree， and distant metastasis （P < 0.05）. The area under the curve （AUC） values of AKT1， ISOC1， and their combined diagnosis for gastric cancer were 0.735， 0.726， and 0.875 respectively （P < 0.05）. The sensitivities were 60.00%， 56.70%， and 75.60%， while the specificities were 85.60%， 83.30%， and 87.80%. The AUC value of the combined detection of AKT1 and ISOC1 in the diagnosis of gastric cancer was higher than that of AKT1 or ISOC1 alone （Z = -3.003， -3.196， P < 0.05）. Conclusions AKT1 and ISOC1 are highly expressed in gastric cancer tissues， and their expressions are upregulated with the progression of the disease. The combined detection of their expression levels holds great significance for the diagnosis and prognosis assessment of gastric cancer.

Key words: serine/threonine kinase 1, isochorismatase domain-containing 1, clinical features, degree of differentiation, lymph node metastasis

CLC Number:

R735.2

Jiangqiao ZHAO,Liping FU,Long YANG,Zhiqiang DONG,Shuli SONG,Benxin YANG. Expression and diagnostic value of serine⁃threonine kinase 1 and isochorismatase domain⁃containing 1 in gastric cancer[J]. The Journal of Practical Medicine, 2025, 41(13): 2033-2038.

Figures/Tables 9

Tab.1

Tab.2

Tab.3

Tab.4

Tab.5

Fig.1

Tab.6

Tab.7

Fig.2

References 26

[1]	易嘉欣，张扬雨，付颖利，等. MEIS1表达对胃癌根治术后患者生存期的影响及其在预后评估中的价值［J］. 吉林大学学报（医学版），2024，50（5）：1358-1364.
[2]	张浩，张震，王秋生，等. FJX1在胃癌组织中高表达并与不良预后相关［J］. 南方医科大学学报，2023，43（6）：975-984.
[3]	BHAVE M A， QUINTANILHA J C F， TUKACHINSKY H， et al. Comprehensive genomic profiling of esr1， pik3ca， akt1， and pten in hr（+）her2（-） metastatic breast cancer： Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice［J］. Breast Cancer Res Treat，2024，207（3）：599-609. doi:10.1007/s10549-024-07376-w doi: 10.1007/s10549-024-07376-w
[4]	汪斐，刘佩，胡楠. 贝伐珠单抗辅助PD-1抑制剂治疗胃癌对血清miR-20a-5p和miR-515-3p的影响研究［J］. 中国癌症杂志，2024，34（5）：493-500.
[5]	叶梦楠，武鸿美，梅琰，等. CREM在胃癌中高表达并与患者的不良预后相关［J］. 南方医科大学学报，2024，44（9）：1776-1782.
[6]	HUANG T T， CHIANG C Y， NAIR J R， et al. Akt1 interacts with dhx9 to mitigate R loop-induced replication stress in ovarian cancer［J］. Cancer Res，2024，84（6）：887-904. doi:10.1158/0008-5472.can-23-1908 doi: 10.1158/0008-5472.can-23-1908
[7]	杨晶晶，殷丽霞，段婷，等. 胃癌组织中高表达ATP5A1与患者术后的不良预后和肿瘤细胞的糖代谢有关［J］. 南方医科大学学报，2024，44（5）：974-980.
[8]	熊珊，申洪. IGFBP1在胃癌组织中的表达特点及其预后作用与机制的生物信息学分析［J］. 中国医学物理学杂志，2024，41（5）：628-639.
[9]	卢顺利，李洪涛，于建平，等. 血清甲胎蛋白阳性胃癌患者临床病理特征与预后关系的研究［J］. 中国肿瘤临床，2023，50（1）：30-36.
[10]	曹一鑫，李峄清，殷润婷. 胃癌组织中PRMT5的表达与临床病理特征和预后的关系［J］. 中国现代医学杂志，2023，33（6）：14-19.
[11]	JANJIGIAN YY， KAWAZOE A， BAI Y， et al. Pembrolizumab plus trastuzumab and chemotherapy for her2-positive gastric or gastro-oesophageal junction adenocarcinoma： Interim analyses from the phase 3 keynote-811 randomised placebo-controlled trial［J］. Lancet， 2023，402（10418）：2197-2208. doi:10.1016/s0140-6736(23)02033-0 doi: 10.1016/s0140-6736(23)02033-0
[12]	陈静，于红刚，范彦，等. 阿霉素诱导磷脂酰肌醇3'-激酶丝氨酸/苏氨酸蛋白激酶FKHRL1通路对胃癌细胞化疗耐药性的影响［J］. 中国实用内科杂志（前沿版），2006，26（4）：272-274.
[13]	DENT R A， KIM S B， OLIVEIRA M， et al. Ipatasertib plus paclitaxel for patients with pik3ca/akt1/pten-altered locally advanced unresectable or metastatic triple-negative breast cancer in the ipatunity130 phase III trial［J］. Clin Cancer Res，2024，30（19）：4329-4338. doi:10.1158/1078-0432.ccr-24-0465 doi: 10.1158/1078-0432.ccr-24-0465
[14]	耿志军，黄菊，李晴晴，等. 丝氨酸/苏氨酸磷酸蛋白磷酸酶4C在胃癌中的表达水平及其与预后的相关性［J］. 中国医学科学院学报，2023，45（5）：721-729.
[15]	刘冬，雷昕奕，宋丹军，等. 碳水化合物磺基转移酶1的表达在胃癌中的预后价值及机制［J］. 中华实验外科杂志，2023，40（2）：219-223.
[16]	FRANCIA M G， OSES C， ROBERTI S L， et al. Sumoylation and the oncogenic E17K mutation affect AKT1 subcellular distribution and impact on Nanog-binding dynamics to chromatin in embryonic stem cells［J］. J Struct Biol，2023，215（2）：107961. doi:10.1016/j.jsb.2023.107961 doi: 10.1016/j.jsb.2023.107961
[17]	张磊，孙晓娜，张丽，等. 胃癌组织中E-cadherin、Vimentin和错配修复相关蛋白的表达及与患者预后的关系［J］. 现代肿瘤医学，2023，31（18）：3420-3427.
[18]	DILAWARI A， BUTURLA J， OSGOOD C， et al. Us food and drug administration approval summary： Capivasertib with fulvestrant for hormone receptor-positive， human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer with pik3ca/akt1/pten alterations［J］. J Clin Oncol，2024，42（34）：4103-4113. doi:10.1200/jco.24.00427 doi: 10.1200/jco.24.00427
[19]	张杰东，刘兰侠，刘杜先，等. 胃癌组织CDK12、SIRT6蛋白表达变化及其与临床病理特征和预后的关系［J］. 山东医药，2023，63（1）：55-58.
[20]	姬汉书，王鹏，顾小红. LINC00963表达水平与胃癌患者临床病理特征和预后的关系［J］. 中华实验外科杂志，2024，41（11）：2573-2576.
[21]	GAO B， ZHAO L， WANG F， et al. Knockdown of isoc1 inhibits the proliferation and migration and induces the apoptosis of colon cancer cells through the akt/gsk-3β pathway［J］. Carcinogenesis，2020，41（8）：1123-1133. doi:10.1093/carcin/bgz188 doi: 10.1093/carcin/bgz188
[22]	KUSHNAREVA Y， MATHEWS I T， ANDREYEV A Y， et al. Functional analysis of immune signature genes in th1* memory cells links isoc1 and pyrimidine metabolism to ifn-γ and il-17 production［J］. J Immunol，2021，206（6）：1181-1193. doi:10.4049/jimmunol.2000672 doi: 10.4049/jimmunol.2000672
[23]	崔海康，张旭东，李晓宁，等. 细胞焦亡分型和APOD预测胃癌患者预后作用的生物信息学分析［J］. 吉林大学学报（医学版），2023，49（5）：1268-1279.
[24]	SHITARA K， RHA S Y， WYRWICZ L S， et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer （keynote-585）： An interim analysis of the multicentre， double-blind， randomised phase 3 study［J］. Lancet Oncol，2024，25（2）：212-224. doi:10.1016/s1470-2045(23)00541-7 doi: 10.1016/s1470-2045(23)00541-7
[25]	李小虹，周丽娜，史蓓蕾，等. 老年胃癌患者血清CA72-4、CA19-9表达水平与外周血N/L比值的相关性［J］. 中国老年学杂志，2022，42（11）：2657-2660.
[26]	张宗兵，乐正宏，刘牧林，等. ITGB2在胃癌中的表达及其临床价值［J］. 中华全科医学，2024，22（7）：1102-1107.

免疫组化结果判定	内容	分值
染色强度评分标准	无色	0
	淡黄色	1
	棕黄色	2
	褐色或黑色	3
阳性细胞占比评分标准	≤ 5%	0
	6% ~ 10%	1
	11% ~ 50%	2
	51% ~ 75%	3
	> 75%	4

组别	例数	AKT1		ISOC1
组别	例数	阳性表达	阴性表达	阳性表达	阴性表达
癌组织	90	68（75.56）	22（24.44）	59（65.56）	31（34.44）
癌旁组织	90	36（40.00）	54（60.00）	26（28.89）	64（71.11）
χ² 值		23.320		24.275
P值		< 0.001		< 0.001

组别	例数	AKT1阳性评分	ISOC1阳性评分
癌组织	90	5.00（3.75，6.00）	5.00（2.75，6.00）
癌旁组织	90	3.00（2.00，4.00）	2.00（2.00，4.00）
Z值		-5.523	-5.310
P值		0.009	< 0.001

临床特征	例数	AKT1阳性评分	Z值	P值	ISOC1阳性评分	Z值	P值
性别			0.932	0.351		-0.858	0.391
男	46	5.00（2.00，6.00）			5.00（2.00，6.00）
女	44	5.00（4.00，6.00）			5.00（3.00，6.00）
年龄			0.607	0.544		-0.199	0.842
> 60岁	51	5.00（4.00，6.00）			5.00（2.00，6.00）
≤ 60岁	39	5.00（2.00，6.00）			5.00（3.00，6.00）
肿瘤最大径			0.072	0.943		-0.390	0.697
≥ 5 cm	36	5.00（2.00，6.00）			5.00（3.00，6.00）
< 5 cm	54	5.00（4.00，6.00）			5.00（4.00，6.00）
分化程度			3.537	0.000		-3.549	0.000
低分化	47	5.00（5.00，6.00）			6.00（4.00，6.00）
高中分化	43	4.00（2.00，5.00）			4.00（1.00，6.00）
临床分期			3.328	0.001		-3.259	0.001
Ⅲ~Ⅳ期	49	5.00（4.50，6.00）			6.00（4.00，6.00）
Ⅰ~Ⅱ期	41	4.00（2.00，5.50）			3.00（1.50，6.00）
淋巴结转移			5.064	0.000		-4.966	0.000
有	29	6.00（5.00，6.00）			6.00（5.50，6.50）
浸润程度			4.219	0.002		-4.249	0.000
T_3~4	50	5.50（5.00，6.00）			6.00（4.00，6.00）
T_1~2	40	4.00（2.00，5.00）			3.00（1.25，5.00）
远处转移			3.640	0.000		-2.501	0.012
有	17	6.00（6.00，6.00）			6.00（4.50，6.00）

指标	AKT1		ISOC1
指标	r_s 值	P值	r_s 值	P值
分化程度	0.375	0.040	0.376	0.003
临床分期	0.353	0.014	0.345	0.001
淋巴结转移	0.537	< 0.001	0.526	< 0.001
浸润程度	0.447	0.001	0.450	< 0.001
远处转移	0.386	< 0.001	0.265	0.002

Expression and diagnostic value of serine⁃threonine kinase 1 and isochorismatase domain⁃containing 1 in gastric cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 9

References 26

Related Articles 15

Recommended Articles

Metrics

Comments

变量	B	标准误	Wald	P值	OR	95%CI
AKT1	0.261	0.126	4.318	0.038	1.298	1.015 ~ 1.661
ISOC1	0.266	0.115	5.369	0.021	1.304	1.042 ~ 1.633

检验结果变量	AUC	标准误	95%CI	Cut-off	约登指数	敏感度	特异度
AKT1	0.735	0.038	0.660 ~ 0.810	4.50	0.456	0.600	0.856
ISOC1	0.726	0.038	0.651 ~ 0.801	4.50	0.400	0.567	0.833
两项联合	0.875	0.027	0.822 ~ 0.928	0.42	0.634	0.756	0.878

[1]	Changhui WU,Zhiping HUANG,Huiping DAI,Huifang QIU,Chun HE,Fang. TANG. Energy efficiency of contrast⁃enhanced ultrasound combined with TERT promoter mutation to construct a nomogram model for the prediction of concomitant cervical lymph node metastasis in PTMC [J]. The Journal of Practical Medicine, 2025, 41(5): 756-765.
[2]	Jinlan GUO,Xiaoning ZHANG,Jiahui JIANG,Tao. YUAN. Expression of ACTN1 in cutaneous squamous cell carcinoma and its correlation with clinicopathological features and prognosis [J]. The Journal of Practical Medicine, 2025, 41(2): 232-237.
[3]	Bingjie QUAN,Yijing LIU,Xiaoqin LI,Fang ZHOU. Clinical features of hepatitisassociatedaplastic anemia in children [J]. The Journal of Practical Medicine, 2025, 41(1): 84-89.
[4]	Xiuqin TAN,Shunyou DENG,Caimao HUANG,Enzhong LI,Xiaoyan. CHEN. The correlation between trace elements selenium and iodine and thyroid nodules in Guangzhou area [J]. The Journal of Practical Medicine, 2024, 40(8): 1153-1159.
[5]	Jianliang YAN,Zeyu XIE,Rongrong JING,Ming. CUI. Research on establishing gastric cancer lymph node metastasis prediction model based on machine learning and routine laboratory indicators [J]. The Journal of Practical Medicine, 2024, 40(6): 844-849.
[6]	Ming HOU,Youqiang LI,Xuemei LI,Junfeng JIA,Junying CHANG. Construction of a risk prediction model of lung involvement based on chest CT and clinical features in patients with primary Sjogren's syndrome [J]. The Journal of Practical Medicine, 2024, 40(3): 400-405.
[7]	Ying LIU,Yun LIU,Jiahui LIU,Lu WANG,Wenrui HOU,Xiaoli LI,Junxin XIANG,Dianming. LI. An analysis on clinical characteristics in patients with lung adenocarcinomas tested positive for EGFR mutation in pleural effusion [J]. The Journal of Practical Medicine, 2024, 40(1): 43-47.
[8]	Guang YANG,Danfeng ZHANG,Xiaona FENG,Yan. ZHANG. Expression of programmed cell death protein 5 in cervical cancer and its relationship with lymph node metastasis [J]. The Journal of Practical Medicine, 2023, 39(24): 3210-3213.
[9]	Xiran SHI,Heng WANG,Libing HE,Zhiqiang QIU,Hongjian LI,Xiaoxue. XU. Advance in predicting lymph node metastasis of breast cancer by multimodal MRI [J]. The Journal of Practical Medicine, 2023, 39(22): 2861-2865.
[10]	LU Shanming, LUO Wenjuan, LIU Kun, XUE Xiangxing, XIE Yuzhen.. Predictive value of tumor budding for lymph node metastasis of stage ⅠA2⁃ⅠB1 squamous cell carcinoma of the cervix [J]. The Journal of Practical Medicine, 2022, 38(7): 868-872.
[11]	HUANG Chunming, HU Zhongwei, HUANG Yun, ZHAN Yuanjing.. Relationship between early viral load and clinical characteristics of Delta variant of SARS⁃Cov⁃2 [J]. The Journal of Practical Medicine, 2022, 38(5): 532-536.
[12]	GAO Jun⁃ rong, CAO Manqing, ZHANG Xuejun, DENG Yinghong.. Conventional ultrasonographic features of different molecular subtypes of female breast cancer [J]. The Journal of Practical Medicine, 2022, 38(18): 2259-2265.
[13]	LI Wenxiao, LIU Yan, CAO Chunli, WU Fang, CAO Yuwen, CHENG Jing, LI Jun.. The value of conventional ultrasound combined with contrast⁃enhanced ultrasound for predicting axillary lymph node metastasis of breast cancer [J]. The Journal of Practical Medicine, 2022, 38(18): 2272-2278.
[14]	HUANG Shasha, HAN Zheng, TAN Jie, LIU Meng, TIAN Xia.. Expression of tumor suppressor M，Id ⁃ 1 and Foxp3 in gastric cancer tissues and their correlation with pathological characteristics [J]. The Journal of Practical Medicine, 2021, 37(9): 1150-1154.
[15]	CHENG Cheng, XU Rixin, ZHANG Qiang, CAO Tianqing, LIU Xiaodong, XIE Yong, MEI Hongbin.. Clinical features of patients with spontaneous coronary artery dissection and follow⁃up for different treat⁃ments [J]. The Journal of Practical Medicine, 2021, 37(3): 348-352.